Neoadjuvant PD-1 blockade: a new treatment option for patients with early-stage mismatch repair deficient solid tumors

By afschroeder • August 26, 2025

Anderson KG, Ribas A. Neoadjuvant PD-1 blockade: a new treatment option for patients with early-stage mismatch repair deficient solid tumors. J Immunother Cancer. 2025 Aug 25;13(8):e013061. doi: 10.1136/jitc-2025-013061. PMID: 40854816.

Tags: Biomarker, Circulating tumor DNA - ctDNA, colorectal cancer, Hematology/Oncology, immune checkpoint inhibitor, Mismatch repair - MMR, Publications

Longitudinal Study on the Influence of Physical Activity in Managing Fatigue in Patients With Colorectal Cancer

Liu L, Kazemian E, Loroña NC, Shirazipour C, Gong J, Crowder SL, Nguyen N, Damerell V, Mooney K, Playdon MC, Ulrich CM, Li CI, Shibata[...]

Polycyclic aromatic hydrocarbons, gut microbiome composition, impulsivity, and attention covary in a human cohort

Hammer AJ, Kasschau KD, Davis Ii EW, Hoffman P, Johnson-Camacho K, Alexiev A, Anderson K, Shannon J, Marriott LK, Sharpton TJ. Polycyclic aromatic hydrocarbons, gut[...]

Tamibarotene with venetoclax and azacitidine in RARA+ acute myeloid leukemia: results from the SY-1425-202 study

Cluzeau T, Borate U, McMahon C, Fenaux P, Heiblig M, Peterlin P, Ball B, Chantepie S, Eghtedar A, Kambhampati S, Solh M, Torregrosa-Diaz J, Braun[...]